Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21. https://doi.org/10.1111/j.1464-410X.2008.07497.x

Gacci M, Ficarra V, Sebastianelli A et al (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 11:1554–1566. https://doi.org/10.1111/jsm.12525

Article  CAS  PubMed  Google Scholar 

Sebastianelli A, Spatafora P, Morselli S et al (2020) Tadalafil alone or in combination with Tamsulosin for the management for LUTS/BPH and ED. Curr Urol Rep 21:56. https://doi.org/10.1007/s11934-020-01009-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140. https://doi.org/10.1016/j.eururo.2013.03.004

Article  PubMed  Google Scholar 

Nichol MB, Knight TK, Wu J et al (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181:2214–2221. https://doi.org/10.1016/j.juro.2009.01.033

Article  PubMed  Google Scholar 

Lukacs B, Cornu J-N, Aout M et al (2013) Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. Eur Urol 64:493–501. https://doi.org/10.1016/j.eururo.2013.02.026

Article  PubMed  Google Scholar 

Cindolo L, Pirozzi L, Fanizza C et al (2015) Drug adherence and clinical outcomes for patients under Pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68:418–425. https://doi.org/10.1016/j.eururo.2014.11.006

Article  PubMed  Google Scholar 

Shortridge E, Donatucci C, Donga P et al (2017) Adherence and persistence patterns in medication use among men with lower urinary tract symptoms/benign prostatic hyperplasia. Am J Mens Health 11:164–169. https://doi.org/10.1177/1557988315616676

Article  PubMed  Google Scholar 

Ayele HT, Reynier P, Azoulay L et al (2021) Trends in the Pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. World J Urol 39:2019–2028. https://doi.org/10.1007/s00345-020-03429-z

Article  CAS  PubMed  Google Scholar 

Burnett AL, Walker DR, Feng Q et al (2020) Undertreatment of overactive bladder among men with lower urinary tract symptoms in the united States: A retrospective observational study. Neurourol Urodyn 39:1378–1386. https://doi.org/10.1002/nau.24348

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miñana B, Molero JM, Agra Rolán A et al (2021) Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain. Int J Clin Pract 75:e14250. https://doi.org/10.1111/ijcp.14250

Article  CAS  PubMed  Google Scholar 

Barry MJ, O’Leary MP (1995) Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 22:299–307

Article  CAS  PubMed  Google Scholar 

Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 68:318–323. https://doi.org/10.1016/j.urology.2006.02.042

Article  PubMed  Google Scholar 

Cornu JN, Gacci M, Hashim H et al (2023) EAU guidelines on Non-Neurogenic male lower urinary tract symptoms (LUTS), incl. In: EAU Guidelines. Benign Prostatic Obstruction (BPO)

Sandhu JS, Bixler BR, Dahm P et al (2024) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol 211:11–19. https://doi.org/10.1097/JU.0000000000003698

Article  PubMed  Google Scholar 

Hutchison A, Farmer R, Verhamme K et al (2007) The efficacy of drugs for the treatment of Luts/BPH, A study in 6 European countries. Eur Urol 51:207–216. https://doi.org/10.1016/j.eururo.2006.06.012

Article  CAS  PubMed  Google Scholar 

Neu S, Matta R, Locke J et al (2023) Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications in Canada: A retrospective population-based study. Urology 180:219–226. https://doi.org/10.1016/j.urology.2023.06.029

Article  PubMed  Google Scholar 

Ali M, Landeira M, Covernton PJO et al (2021) The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study. BMC Urol 21:119. https://doi.org/10.1186/s12894-021-00881-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of Doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398. https://doi.org/10.1056/NEJMoa030656

Article  CAS  PubMed  Google Scholar 

Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and Tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combat study. Eur Urol 57:123–131. https://doi.org/10.1016/j.eururo.2009.09.035

Article  CAS  PubMed  Google Scholar 

Zabkowski T, Saracyn M (2018) Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol 69. https://doi.org/10.26402/jpp.2018.4.14

Malde S, Lam W, Adwin Z, Hashim H (2021) Pharmacological and interventional treatment of benign prostatic obstruction: an evidence-based comparative review. BJUI Compass 2:238–259. https://doi.org/10.1002/bco2.74

Article  PubMed  PubMed Central  Google Scholar 

Anger JT, Goldman HB, Luo X et al (2018) Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the united States. Neurourol Urodyn 37:213–222. https://doi.org/10.1002/nau.23276

Article  PubMed  Google Scholar 

Soda T, Tashiro Y, Koike S et al (2020) Overactive bladder medication: persistence, drug switching, and reinitiation. Neurourol Urodyn 39:2527–2534. https://doi.org/10.1002/nau.24527

Article  PubMed  Google Scholar 

Matsukawa Y, Takai S, Funahashi Y et al (2017) Effects of withdrawing α1-blocker from combination therapy with α1-blocker and 5α-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A prospective and comparative trial using urodynamics. J Urol 198:905–912. https://doi.org/10.1016/j.juro.2017.05.031

Article  CAS  PubMed  Google Scholar 

van der Worp H, Jellema P, Hordijk I et al (2019) Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms: a systematic review and meta-analysis. BMJ Open 9:e030405. https://doi.org/10.1136/bmjopen-2019-030405

Article  PubMed  PubMed Central  Google Scholar